The Food and Drug Administration recently announced approval of Syfovre as a treatment for the severe form of macular degeneration known as geographic atrophy.
Geographic atrophy occurs when the retina is damaged causing the loss of
central vision. Syfovre is an injection that targets inflammation, which is the primary cause of macular degeneration. While Syfovre will not reverse the disease, it can slow the progression.
Geographic atrophy typically affects people over the age of 50 and is one of the main causes of vision loss in the United States, affecting at least one million people.
Syfovre is now available and is administered via injection every one or two months at a cost of $2,190 per vial. Syfovre is manufactured by Apeillis Pharmaceuticals.
